A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Naftopidil is an alpha-1 adrenergic receptor-blocking agent commonly used for benign prostatic hyperplasia (BPH) in Japan. Our previous retrospective study demonstrated a significantly lower incidence of prostate cancer in BPH men treated with naftopidil (1.8%) compared with those with tamsulosin (3.1%). Currently we are attempting to confirm the suppressive effect of naftopidil on prostate carcinogenesis in a prospective randomized study. Methods: This multicenter, randomized, open-labeldoi:10.15761/pmch.1000106 fatcat:tzsvb5solvey7dg4h2cmgkwvdi